Background. Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer. Methods. Eighty-three patients with stage III-1V non-small cell lung cancer received 3 to 4 cycles of carboplatin AUC 5 on day 2 and gemcitabine 1250 mg/m 2 on days 1 and 8 every 21 days. Results. The overall response rate was 43.4%. Results obtained from elderly and non- elderly groups were compared using the logrank method. Median overall survival and progression-free survival were 11 and 7 months, respectively (12 and 7 months, non- elderly group; 6.5 and 5 months, elderly group, P = 0.28 and 0.25 respectively). Grade 3-4 toxicity included neutropenia, thrombocytopenia, anemia, nausea/vomiting, and diarrhea. Incidences of grade 3-4 toxicity were similar for elderly and non-elderly patients. Conclusions. Data confirm that carboplatin-gemcitabine is an active and well-tolerated regimen in advanced non-small cell lung cancer and could be investigated in elderly patients.
|Number of pages||7|
|Publication status||Published - Jan 2009|
- Non-small-cell lung cancer
ASJC Scopus subject areas
- Cancer Research